Revenue → Gross Profit: $13.1BCardiometabolic health → Revenue: $11.3BGross Profit → Operating profit: $6.8BGross Profit → Operating cost: $6.3BOperating profit → Net Profit: $5.7BMounjaro → Cardiometabolic health: $5.2BZepbound → Cardiometabolic health: $3.4BOperating cost → R&D: $3.3BOperating cost → Marketing, S&A: $2.8BRevenue → Cost of Revenue: $2.4BOncology → Revenue: $2.4BVerzenio → Oncology: $1.5BImmunology → Revenue: $1.3BOperating profit → Taxes: $1.1BTrulicity → Cardiometabolic health: $1.1BOther cardiometabolic → Cardiometabolic health: $1.0BOther oncology → Oncology: $0.9BTaltz → Immunology: $0.8BJardiance → Cardiometabolic health: $0.7BOther immunology → Immunology: $0.4BNeuroscience → Revenue: $0.3BOther → Revenue: $0.2BOperating cost → Acquired IPR&D: $0.2BOperating cost → Other expense: $0.1BAcquired IPR&D$0.2B-0% Y/YCardiometabolic health$11.3B51% Y/YCost of Revenue$2.4B13% Y/YGross Profit$13.1B44% Y/YImmunology$1.3B16% Y/YJardiance$0.7B-10% Y/YMarketing, S&A$2.8B30% Y/YMounjaro$5.2B68% Y/YNet Profit$5.7B91% Y/YNeuroscience$0.3B1% Y/YOncology$2.4B12% Y/YOperating cost$6.3B13% Y/YOperating profit$6.8B93% Y/YOther$0.2B-3% Y/YOther cardiometabolic$1.0B-16% Y/YOther expense$0.1B-54% Y/YOther immunology$0.4B58% Y/YOther oncology$0.9B12% Y/YR&D$3.3B23% Y/YRevenue$15.6B38% Y/YTaltz$0.8B3% Y/YTaxes$1.1B103% Y/YTrulicity$1.1B-12% Y/YVerzenio$1.5B12% Y/YZepbound$3.4B172% Y/YEli Lilly Q2 FY25 Income Statementcreated with SankeyArt.com
2024
Q1 Q2 Q3
2025
Q2
Copy and edit diagram